Want to see SNDX full AI Analyst Report?
SNDX Stock Chart & Stats
$24.23
$0.12(0.87%)
At close: 4:00 PM EST
$24.23
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$9.38 - $25.59
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.31M
Market Cap
$2.01B
Enterprise Value$2.05K
Total Cash (Recent Filing)$352.06M
Total Debt (Recent Filing)$345.36M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 10, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.80
Shares Outstanding88,610,020
10 Day Avg. Volume1,880,279
30 Day Avg. Volume2,307,650
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)28.16
Price to Sales (P/S)10.56
P/FCF Ratio-5.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.67Price Target Upside59.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$343.79M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginsSyndax’s ~26% TTM revenue growth paired with ~96% gross margins reflects durable product-level economics and commercial traction. High gross margin provides structural leverage as revenue scales, allowing incremental sales to disproportionately improve gross profit and support long-term margin expansion if fixed costs are absorbed.
Materially Improved Leverage (debt Eliminated)Reporting TTM debt of $0 reduces solvency risk and interest burden, giving management durable financial flexibility to prioritize R&D or commercialization. A debt-free capital structure improves optionality for strategic investments, licensing or M&A without fixed-interest pressure that could otherwise strain cash flow.
Broader Late‑stage Pipeline And New ProgramsThe addition of a mutant‑selective EGFR, a next‑gen menin inhibitor and multiple late‑stage programs diversifies Syndax’s development portfolio. Multiple programs and upcoming catalysts create a multi‑asset growth trajectory, reducing binary risk from a single asset and improving long‑term revenue optionality if trials succeed.
Bears Say
Heavy Operating Cash BurnSyndax’s ~-$278M TTM operating and free cash flow is a persistent structural drain that forces repeated external financing or rapid operational tightening. Large cash burn constrains strategic flexibility, increases capital markets dependence, and raises the probability of equity dilution until sustainable positive cash generation is achieved.
Deep Ongoing Net LossesA TTM net loss of roughly $243M and very negative margins indicate the business is not yet profitable. Persistent losses erode resources and equity, force prioritization of programs, and elevate the need for dilutive financings or spending cuts absent clear and sustained revenue scaling or major clinical successes.
Thin Shareholder Equity / Reliance On External FundingWith only ~ $42M of equity against sizable losses and cash burn, the balance sheet has limited shock‑absorption. This structural thinness increases sensitivity to adverse clinical or market events and makes continued external funding — often dilutive or covenant‑bearing — a likely necessity until profitability or cash neutrality is achieved.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc.’s price range in the past 12 months?
Syndax Pharmaceuticals Inc. lowest stock price was $9.38 and its highest was $25.59 in the past 12 months.
What is Syndax Pharmaceuticals Inc.’s market cap?
Syndax Pharmaceuticals Inc.’s market cap is $2.01B.
When is Syndax Pharmaceuticals Inc.’s upcoming earnings report date?
Syndax Pharmaceuticals Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 22 days.
How were Syndax Pharmaceuticals Inc.’s earnings last quarter?
Syndax Pharmaceuticals Inc. released its earnings results on Apr 30, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.608 by $0.128.
Is Syndax Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc.’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc. pay dividends?
Syndax Pharmaceuticals Inc. does not currently pay dividends.
What is Syndax Pharmaceuticals Inc.’s EPS estimate?
Syndax Pharmaceuticals Inc.’s EPS estimate is -0.48.
How many shares outstanding does Syndax Pharmaceuticals Inc. have?
Syndax Pharmaceuticals Inc. has 88,610,020 shares outstanding.
What happened to Syndax Pharmaceuticals Inc.’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.608. Following the earnings report the stock price went down -10.826%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in SNDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syndax Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (59.58% Upside)
$38.67 (59.58% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.78%
12-Months-Change
Fundamentals
Return on Equity
-256.66%
Trailing 12-Months
Asset Growth
-26.23%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
SNDX Stock 12 Month Forecast
Average Price Target
$38.67
▲(59.58% Upside)
Technical Analysis
Ownership Overview
1.61% Insiders
15.46% Mutual Funds
0.60% Other Institutional Investors
65.78% Public Companies and
Individual Investors